As we saw in the earlier charts, Novo Nordisk continues to increase its market share in GLP-1-based diabetes treatments, reaching 55.1%—its highest level to date—despite growing competition.

In “Summer of Fire and Blood,” Lyndal Roper tells the story of the serfs who fought for a better life and the elites who co-opted their movement. By Thomas Meaney Tell us a few things about ...

Based on an average trading volume of 8,100,000 shares, the short-interest ratio is presently 1.7 days. Institutional Trading of Novo Nordisk A/S Several hedge funds have recently modified their ...

Now, semaglutide maker Novo Nordisk is chiming in. The commercial takes aim at the broader U.S. weight loss industry as well as makers of GLP-1 drugs for obesity, which are “priced for profits ...

Novo Nordisk gets CHMP backing for oral GLP-1 agonist Rybelsus in its marketing battle with Eli Lilly, plus positive opinions for Bayer’s diabetes drug Nubeqa, Emergent’s cholera vaccine, and more ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...

The future of GLP-1 drugs is looking bigger than anyone predicted. As governments consider broader adoption and competitors scramble to keep up, Novo Nordisk is well-positioned to lead this ...

Does the Smart #1 deserve to become as popular as a viral tweet? Or is it as bang on trend as MySpace? That's what we'll tell you in this review. Read on as we find out how it stacks up against ...

Find Nordic Countries Norway Camping Tent stock video, 4K footage, and other HD footage from iStock. Get higher quality Nordic Countries Norway Camping Tent content, for less—All of our 4K video clips ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too worried about the upcoming Medicare price negotiations over blockbuster GLP-1 drugs, even though the company still stands with the industry against ...